Patent cliff

Global Research and Discovery Group Announces Completion of Research with Impact Biomedical

Retrieved on: 
Tuesday, April 11, 2023
ChromeOS, DiscoverIE Group, Disease, University, Therapy, Potomac Institute for Policy Studies, Patent cliff, Center for Strategic and International Studies, SARS, Biodefense, Research, 3F, COVID, HAVEN, Government, Linebacker, Science, Patent, BioForge, Thompson, Cato Institute, Quantum, Technology transfer, ACE2, Fine chemical, Pharmaceutical industry, Vaccine, Management, Bioplastic

WINTER HAVEN, Fla., April 11, 2023 /PRNewswire/ -- Global Research and Discovery Group today announced that is has completed its five-year research project with Impact Biomedical.

Key Points: 
  • WINTER HAVEN, Fla., April 11, 2023 /PRNewswire/ -- Global Research and Discovery Group today announced that is has completed its five-year research project with Impact Biomedical.
  • It is anticipated that the next phase of the research will shift to licensing the Impact Biomedical portfolio to larger pharmaceutical companies for down range development.
  • The end of the active work on this project comes at a key time for Global Research and Discovery, which will shift to identifying potential collaborations for continued research.
  • This becomes an issue since these financial returns are required to support research for newer and more effective biomedical discoveries.

Impact Biomedical and Global Research & Discovery Group Represent a Thriving Example in the Shift in the Biomedical Innovation and Investment Industry

Retrieved on: 
Tuesday, February 14, 2023
Investment, Patent cliff, Development, Intellectual property, World Health Organization, Safety, Philosophy, Patient, Biomedical Research, Research, Risk, ZS, Discovery, Discovery and development of non-nucleoside reverse-transcriptase inhibitors, Pharmacy, Phase II, Global Research, FDA, Growth, Volunteering, J. P. Morgan, HAVEN, ZS Associates, DiscoverIE Group, Medical device, Renewable energy, Pharmaceutical industry, Generic drug

WINTER HAVEN, Fla., Feb. 14, 2023 /PRNewswire/ -- Impact BioMedical, in concert with its research partner Global Research and Discovery Group, find themselves in the right place at the right time as the biomedical investment industry shifts toward Discovery-phase funding in biomedical research, licensing and intellectual property and away from waiting until Phase 2 or Phase 3 clinical trials. This shift sets the partnering companies on a path that could help stabilize the future of the industry.

Key Points: 
  • This shift sets the partnering companies on a path that could help stabilize the future of the industry.
  • That early investment in biomedical research is on the rise should not come as a surprise to those who have watched the market develop over time.
  • The one bright spot was that more investment came early in the research process, which, since the early 2000s has taken larger shares of the investment dollar.
  • "Now, more than ever, Discovery is the key to the immediate future of biomedical innovation."

Impact BioMedical Scientific Partner GRDG Sciences to be Featured in New Documentary

Retrieved on: 
Wednesday, October 19, 2022
Diamond, Quantum, Lists of record labels, Investment management, Cholera, Therapy, Science, R, DSS, OTC, Digital transformation, Solution, Freedom, Escherichia coli, Severe acute respiratory syndrome coronavirus 2, LLC, NYSE, Plastic, Alternative trading organization, Cancer, Prophase, Patent cliff, DARPA, Biomedicine, GLOBE, Leadership, Mission: Impossible, Tuberculosis, Research, NIH, Security (finance), Technology, Thompson, MRSA, COO, IPO, Emmy Awards, Sustainable energy, Biosafety, Partnership, Infection, Drug discovery, Linebacker, Epidemic Intelligence Service, Safety, Tom Denney, COVID-19, Pharmaceutical industry, Toy, Fine chemical, Management, Vaccine, Film, Biotechnology, Rhinovirus

ROCHESTER, N.Y., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Daryl Thompson, founder of GRDG Sciences LLC (“GRDG”) in Winter Haven, Florida, has spent a career working just out of the spotlight and inventing biological and medical technologies that, when fully deployed, could better the lives of people around the world.

Key Points: 
  • Early in the development process, GRDG began a working relationship with Impact Biomedical, who partnered with GRDG and provided investment capital to support its research.
  • Impact BioMedical, Inc. ("Impact BioMedical") is a wholly owned subsidiary of DSS.
  • Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades.
  • By tapping into the scientific expertise of GRDG Sciences, LLC, Impact BioMedical pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno -related diseases.

"A Real-Life Mission Impossible" -- Global Research and Discovery Group Steps in The Spotlight for Documentary, "The BioQuest" -- Filming to Start December 3

Retrieved on: 
Thursday, October 20, 2022
Diamond, Quantum, Cholera, MRSA, Therapy, Science, Mission: Impossible, Tuberculosis, Escherichia coli, Severe acute respiratory syndrome coronavirus 2, Plastic, Emmy Awards, Research, NIH, Biosafety, Partnership, Cancer, Technology, Infection, Linebacker, Prophase, Everglades, Epidemic Intelligence Service, Safety, Patent cliff, OTC, DARPA, Tom Denney, Thompson, COVID-19, Solution, Freedom, HAVEN, Pharmaceutical industry, Management, Vaccine, Film, Rhinovirus

For GRDG, that team included a Washington insider, an investor and a lab.

Key Points: 
  • For GRDG, that team included a Washington insider, an investor and a lab.
  • "The NIH model is great for research, but it takes a long time to get anything done," he said.
  • These new plastics are specifically focused on solutions for common products such as cups, plates, utensils, plastic bags, and countertops.
  • Diamond Studios, an Emmy Award-winning production company from Tampa, Fla., will produce the documentary, which will begin filming in December 2022.

DSS’s Impact BioMedical Successfully Synthesizes First Quantum-Based Compound

Retrieved on: 
Tuesday, September 7, 2021

Impact BioMedical, Inc., a wholly owned subsidiary of Document Security Systems (NYSE American: DSS), and GRDG Sciences initiated the research project called Quantum in Summer 2020.

Key Points: 
  • Impact BioMedical, Inc., a wholly owned subsidiary of Document Security Systems (NYSE American: DSS), and GRDG Sciences initiated the research project called Quantum in Summer 2020.
  • Through the Quantum research project, Impact BioMedical and GRDG have taken the first step in creating a new way to make medicine.
  • Impact BioMedical, Inc. ("Impact BioMedical") is a wholly owned subsidiary of DSS.
  • Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades.

Biosimilar Market: The Future for the Generic Pharmaceuticals Industry

Retrieved on: 
Friday, March 13, 2020
Life sciences, Articles, Biotechnology, Biosimilar, Drugs, Pharmaceutical industry, Biopharmaceutical, Patent cliff, Biologic

Download Exclusive Sample Copy of Report: https://www.infiniumglobalresearch.com/reports/sample-request/6039

Key Points: 
  • Download Exclusive Sample Copy of Report: https://www.infiniumglobalresearch.com/reports/sample-request/6039
    A biosimilar is a biologic product that is highly identical to the original biologic product, known as a reference product.
  • Biosimilar products are large and usually complex molecules produced from living organisms and are keenly monitored to ensure consistent quality.
  • The most important key factor driving the biosimilar market is the patent cliff of prime biological drugs.
  • Based on geographical analysis, the global biosimilar market is categorized into North America, Europe, Asia Pacific and Rest of the World.